Identification of new breast cancer predisposition genes via whole exome sequencing
- MC Southey1,
- DJ Park1,
- F Lesueur2,
- F Odefrey1,
- T Nguyen-Dumont1, 2,
- F Hammet1,
- SL Neuhausen3,
- EM John4,
- IL Andrulis5,
- G Chenevix-Trench6,
- L Baglietto7,
- F Le Calvez-Kelm2,
- M Pertesi2,
- A Lonie8,
- B Pope8,
- O Sinilnikova9,
- H Tsimiklis1,
- GG Giles7,
- JL Hopper10,
- SV Tavtigian11 and
- DE Goldgar12
© Southey et al; licensee BioMed Central Ltd. 2012
Published: 12 April 2012
The application of massively parallel sequencing (MPS) platforms has begun to revolutionize our understanding of the immense variation in the human genome and the complexity that can underlie genetic susceptibility to disease. The utility of exome capture MPS through the identification of genes for rare Mendelian disorders based on analysis of only a few individuals has been eloquently demonstrated. Common diseases such as breast cancer present substantially increased complexity in terms of locus, allelic and phenotypic heterogeneity, as well as complex relationships between genotype and phenotype (reduced penetrance, phenocopies etc.). With careful consideration of study design , thoughtful selection of families from our international resources (whole exome sequencing of two highly selected affected members of multiple-case breast cancer families), and a well-developed strategy (analytical pipeline) for distinguishing the few true breast cancer susceptibility genes from the many genes that have rare genetic variants that could plausibly alter protein function, we are advancing a large program of work aimed at identifying the majority of the “missing heritability” of breast cancer.
Our early findings demonstrate that:
1) despite very plausible biological roles, some genetic variants in some genes predicted to be damaging by SIFT and Polyphen2 do not appear to be associated with breast cancer risk .
2) application of our strategy can identify new breast cancer susceptibility genes. During the early conduct of this program, we identified a family with a protein truncating mutation in a gene involved in DNA repair. Follow-up has included mutation screening of:
a) youngest affected members of 250 multiple-case breast cancer families,
b) cases and controls participating in Australian population-based studies of breast cancer (ABCFS and MCCS)
c) cases and controls in an international population-based case-control-family resource (BCFR)
To date, these analyses have identified 6 families with frameshift or evolutionarily unlikely missense mutations in this gene. Features of these families include multiple-cases of early-onset female breast cancer with some potentially other interesting features such as early-onset male breast cancer and pancreatic cancer. These mutations have not been found in approximately 3000 unaffected population-based controls without a family history of breast cancer.
We are continuing to expand our dataset to include the exome sequences of further families and coordinating the follow-up of candidate genes using appropriate MPS platforms and as founding partners of a newly formed international consortium of breast cancer exome sequencing researchers.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.